ATTO · XBRL financial data
Attovia Therapeutics financial statements, every quarter
The same tables from 1 filing, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters
| In thousands of dollars | Jun 30, 2026 |
|---|---|
| Revenue | 450 |
| Research and development | 18,946 |
| General and administrative | 3,307 |
| Total operating expenses | 22,253 |
| Operating income (loss) | (21,803) |
| Interest income | 1,141 |
| Other income (expense) | (25) |
| Net income (loss) | (20,687) |
| Earnings per share, basic USD per share | (4.88) |
| Earnings per share, diluted USD per share | (4.88) |
| Weighted average shares, basic thousands of shares | 4,238 |
| Weighted average shares, diluted thousands of shares | 4,238 |
Balance sheet
CSVFiscal quarters
| In thousands of dollars | Jun 30, 2026 |
|---|---|
| Cash and cash equivalents | 32,829 |
| Marketable securities | 82,303 |
| Prepaid and other current assets | 3,269 |
| Total current assets | 118,401 |
| Property and equipment, net | 3,343 |
| Right-of-use asset | 3,578 |
| Total assets | 128,348 |
| Accounts payable | 6,002 |
| Accrued liabilities | 4,575 |
| Total current liabilities | 12,615 |
| Lease liability, non-current | 2,288 |
| Total liabilities | 15,581 |
| Accumulated deficit | (150,353) |
| Total stockholders' equity | (145,459) |
| Total liabilities and equity | 128,348 |
| Common shares outstanding (cover page) thousands of shares | 45,651 |
Cash flows
CSVFiscal quarters
| In thousands of dollars | Jun 30, 2026 |
|---|---|
| Net income (loss) | (20,687) |
Compare with peers
SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Attovia Therapeutics | 32,829 | 450 | not reported | 45.7M | — | 10-QJun 30, 2026 |
| Medicinova | 25,416 | 458 | (1,920)* | 49.2M | 13.2 quarters | 10-QJun 30, 2026 |
| Adia Nutrition | 128 | 485 | (109)* | 94.4M | 1.2 quarters | 10-QJun 30, 2026 |
| Palisade Bio | 125,172 | 500 | (7,603)* | 174.3M | 16.5 quarters | 10-QJun 30, 2026 |
| Arvinas | 88,000 | 500 | (10,400)* | 65.5M | 13.0 quarters | 10-QSep 30, 2026 |
| Volitionrx | 2,800 | 399 | (5,160)* | 13.6M | 0.5 quarters | 10-QJun 30, 2026 |
| Milestone Pharmaceuticals | 169,728 | 559 | (22,714)* | 124.5M | 7.5 quarters | 10-QJun 30, 2026 |
| Scienture Holdings | 8,188 | 344 | (3,132)* | 41.1M | 2.6 quarters | 10-QJun 30, 2026 |
| Atara Biotherapeutics | 3,221 | 630 | (3,338)* | 10.0M | 3.0 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.